Magnesium decreases cardiac injury in patients undergoing coronary artery bypass surgery.
BACKGROUND
The calcium-channel blocking effect of magnesium might have protective effects in patients undergoing cardiopulmonary bypass surgery. We assessed the effects of magnesium on hearts undergoing coronary artery bypass surgery with intermittent warm blood hyperkalemic cardioplegia in the antegrade fashion.


METHODS
Twenty patients undergoing coronary bypass surgery were randomly divided into two groups, a control group who received intermittent antegrade warm blood hyperkalemic cardioplegia for myocardial protection, and a study group who received the same solution with the addition of magnesium to the cardioplegia. Extracellular substrates (creatinine phosphokinase, creatinine phosphokinase-MB group, lactate dehydrogenase, c-reactive protein, and cardiac troponin I were measured preoperatively and postoperatively.


RESULTS
There were significant differences in the post-operative concentrations of creatinine phosphokinase, creatinine phosphokinase-MB group, c-reactive protein, and lactate dehydrogenase after cardiopulmonary bypass (P<0.001) in the study group compared with the control subjects. Cardiac troponin I levels were also significantly lower in the study group after cardiopulmonary bypass (P<0.005).


CONCLUSIONS
Our study indicates that if magnesium is added to intermittent antegrade warm blood hyperkalemic cardioplegia, blood levels of many markers of cardiac myocardial injury after cardiopulmonary bypass are lowered. This finding may have implications for myocardial protection.
Resatoglu
Adem Grbolar
AG
Cankaya Hospital, Ankara, Turkey. ademgrbolar@hotmail.com
Demirturk
Orhan Saim
OS
Yener
Nuran
N
Yener
Ali
A
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002314:Cardioplegic Solutions / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D006324:Heart Arrest, Induced / Q000379:methods; D006331:Heart Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*
D015415:Biomarkers; D002121:Calcium Channel Blockers; D002314:Cardioplegic Solutions; D008274:Magnesium